文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-DOTATATE联合卡培他滨治疗恶性副神经节瘤的回顾性研究

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas.
PubMed 文献 · EJNMMI Res · 2019-02-06

该回顾性单中心单臂观察性研究纳入25例晚期恶性副神经节瘤患者,接受177Lu-DOTATATE联合卡培他滨治疗。中位无进展生存期为32个月,中位总生存期未达到,按RECIST 1.1标准的形态学客观缓解率为28%(7/25),生化缓解率(嗜铬粒蛋白A下降>50%)为28%,症状缓解率为43%。与已发表的PRRT单药治疗结果相比,联合方案未显示出明显优势,可能受研究样本量不足所限。

要点

  • 联合方案在恶性副神经节瘤中客观缓解率为28%,症状缓解率为43%。
  • 中位无进展生存期为32个月,中位总生存期未达到。
  • 与PRRT单药历史数据相比未见明显优势,需大样本随机试验验证。

核心结论

  • 177Lu-DOTATATE联合卡培他滨在恶性副神经节瘤患者中可获得28%的客观缓解率和43%的症状缓解率,但与已发表的PRRT单药结果相比未见明显优势,可能因研究样本量不足。

研究设计与样本

  • 回顾性、单中心、单臂、观察性研究,纳入2009年7月至2017年3月间连续接受177Lu-DOTATATE联合卡培他滨治疗的晚期副神经节瘤患者25例。

主要发现

  • 25例患者接受177Lu-DOTATATE平均剂量22.86±9.54 GBq(范围14.43-50 GBq),卡培他滨1250 mg/m2,从PRRT当日早晨起第0至14天给药。
  • 中位总生存期未达到,中位无进展生存期为32个月。
  • 按RECIST 1.1标准形态学客观缓解率为28%(7/25),嗜铬粒蛋白A水平下降>50%的生化缓解率为28%,症状缓解率为43%。

关键数值与推荐

  • 形态学缓解按RECIST 1.1标准评价,客观缓解率为28%(7/25)。
  • 生化缓解定义为嗜铬粒蛋白A水平下降>50%,发生率为28%。
  • 症状缓解率为43%。

临床怎么用

  • 该联合方案可作为晚期恶性副神经节瘤的一种治疗选择,但现有证据尚不足以证明其优于PRRT单药。
  • 临床决策时应结合患者个体情况,并期待大样本随机试验进一步验证卡培他滨作为PRRT放射增敏剂的价值。

局限性

  • 回顾性、单中心、单臂、观察性设计,样本量仅25例,作者指出研究可能因样本量不足而效能不够。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking. The aim of this study was to evaluate the role of combined capecitabine and 177Lu-DOTATATE in malignant PGL patients. METHODS: In this retrospective, single-institutional, single-arm, observational study, data of consecutive advanced stage PGL patients treated with concomitant 177Lu-DOTATATE-capecitabine therapy, between July 2009 and March 2017, were collected and analyzed. RESULTS: Twenty-five PGL patients received an average dose of 22.86 ± 9.54 (14.43-50) GBq 177Lu-DOTATATE and 1250 mg/m2 capecitabine from days 0 to 14, commencing on the morning of PRRT. The median overall survival (OS) was not attained in this patient cohort; however, the median PFS was 32 months. Morphological response according to RECIST 1.1 criteria was achieved in 28% (7/25) patients. Biochemical response with > 50% reduction in chromogranin A levels was observed in 28% of the patients. CONCLUSIONS: Our data confirm that 177Lu-DOTATATE-capecitabine therapy is effective in achieving an objective response in 28% and symptomatic response in 43% patients. In comparison to published PRRT monotherapy outcomes in PGL, we did not observe any great advantage of concomitant therapy; however, it could be due to under-powered study. We recommend a large randomized trial to prove or disprove the utility of capecitabine as a radiosensitizer for PRRT in PGL patients.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Yadav MP, Ballal S, Bal C, et al. Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas. EJNMMI Res. 2019. PMID: 30725219. doi:10.1186/s13550-019-0484-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。